N/A N=140 Assessing Supported Employment With Veterans With Felony Convictions and Mental Illness or Substance Abuse
Employment
Primary: Employment — 8; 21 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=17 Feasibility of Prophylactic Haldol to Prevent Delirium in Cancer Patients
Stem Cell Transplant Complications · Delirium
Primary: Side Effects and Tolerability of Haldol in Patients With Undergoing Hematopoietic Stem Cell Transplant — 1 Adverse Event
Phase 3 N=511 IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose
Iron Deficiency Anaemia
Primary: Number of Subjects With an Haemoglobin (Hb) Increase of ≥ 2 g/dL From Baseline at Any Time From Week 1 to Week 5 — 226; 83 participants
Phase 4 N=27 Intravesicular Onabotulinumtoxin A in Interstitial Cystitis
Interstitial Cystitis
Primary: The Primary Outcome Will be Assessing the Measurement of Subjective Patient Pain Using the O'Leary-Sant Symptom and Problem Indexes. — 10.92; 10.85; 9.75; 9.92 units on…
Phase 2 N=41 Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer
Prostate Cancer
Primary: Metabolic Syndrome — 0; 0 kilograms
Phase 3 N=347 MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects
Asthma
Primary: Number of Participants Who Experienced On-treatment Adverse Events (AE) and On-treatment Serious Adverse Events (SAE) — 326; 79 Participants
Phase 4 N=81 Vascular Inflammation in Psoriasis - Extension Study
Psoriasis · Cardiovascular Disease
Primary: Change in Vascular Inflammation — -3.8 percentage change
Phase 3 N=882 Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass
Coronary Artery Bypass Grafting · Mitral Valve Surgery · Low Cardiac Output Syndrome
Primary: Number of Dual Efficacy Endpoint Events — 56; 48 events
Phase 2 N=24 Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)
Non Small Cell Lung Cancer
Primary: Percentage of Subjects With Detectable Circulating T Cells After Treatment — 16.7 Percentage of participants
Phase 4 N=97 Vascular Inflammation in Psoriasis Trial (The VIP Trial)
Psoriasis · Cardiovascular Disease
Primary: Change in Vascular Inflammation — -.067; -.052; -.079 Tissue-to-background ratio (TBR) — p=0.795
Phase 4 N=108 Neuromuscular Blockade During Transurethral Resection of Bladder Cancer
Neuromuscular Blockade
Primary: Number of Participants Attaining a 5 (Optimal) Surgical Condition Score — 16; 38 Participants
Phase 2 N=15 A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease
Graves' Disease
Primary: Percentage of Participants Whose Thyroid Stimulating Hormone (TSH) Levels Normalize After 12 Week Treatment — 0 percentage of participants
Phase 2 N=103 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent
Anaemia
Primary: Change From Baseline in Hgb Levels at Day 29 — -0.61; -0.19; -0.13; 0.64 g/dL
Phase 2 N=59 Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.
Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia
Primary: Rate of Major Molecular Response (MMR) at 6 Cycles for Ph+ CML CP Patients Resistant or Intolerant to Imatinib or Dasatinib — 39.4 Percentage of participants
N/A N=107 High-resolution, Relational, Resonance-based, Electroencephalic Mirroring (HIRREM) to Relieve Insomnia
Insomnia
Primary: Change From Baseline in Insomnia Severity Index (ISI) — -6.98; -4.94 units on a scale